FY2027 Earnings Estimate for Biogen Inc. Issued By Hsbc Global Res (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Research analysts at Hsbc Global Res increased their FY2027 EPS estimates for shares of Biogen in a research note issued on Monday, July 8th. Hsbc Global Res analyst M. Herholdt now expects that the biotechnology company will post earnings per share of $22.39 for the year, up from their previous forecast of $22.33. The consensus estimate for Biogen’s current full-year earnings is $15.63 per share. Hsbc Global Res also issued estimates for Biogen’s FY2028 earnings at $24.30 EPS.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 24th. The biotechnology company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $3.45 by $0.22. The firm had revenue of $2.29 billion during the quarter, compared to the consensus estimate of $2.31 billion. Biogen had a net margin of 12.07% and a return on equity of 14.83%. The business’s revenue was down 7.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.40 earnings per share.

A number of other research firms have also weighed in on BIIB. Royal Bank of Canada reissued an “outperform” rating and set a $317.00 price target on shares of Biogen in a research report on Wednesday, June 26th. UBS Group reduced their target price on Biogen from $250.00 to $214.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Bank of America dropped their price target on Biogen from $280.00 to $260.00 and set a “neutral” rating on the stock in a report on Friday, April 12th. William Blair restated an “outperform” rating on shares of Biogen in a research note on Wednesday, July 3rd. Finally, Wedbush lifted their target price on Biogen from $213.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, April 25th. Ten research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Biogen presently has a consensus rating of “Moderate Buy” and an average price target of $286.00.

Biogen Stock Down 2.8 %

BIIB stock opened at $230.06 on Thursday. The firm has a market capitalization of $33.50 billion, a PE ratio of 28.72, a P/E/G ratio of 2.34 and a beta of -0.04. The stock’s 50 day moving average is $226.50 and its 200-day moving average is $227.05. Biogen has a twelve month low of $189.44 and a twelve month high of $281.12. The company has a quick ratio of 1.32, a current ratio of 2.10 and a debt-to-equity ratio of 0.41.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Opal Wealth Advisors LLC bought a new stake in shares of Biogen during the second quarter valued at about $46,000. QRG Capital Management Inc. increased its holdings in Biogen by 14.4% during the 2nd quarter. QRG Capital Management Inc. now owns 3,012 shares of the biotechnology company’s stock worth $698,000 after acquiring an additional 378 shares during the period. Capital Investment Advisors LLC lifted its stake in Biogen by 17.1% in the 2nd quarter. Capital Investment Advisors LLC now owns 2,197 shares of the biotechnology company’s stock worth $509,000 after purchasing an additional 321 shares in the last quarter. CX Institutional bought a new position in Biogen in the 2nd quarter valued at $233,000. Finally, Valeo Financial Advisors LLC grew its position in shares of Biogen by 40.7% during the 2nd quarter. Valeo Financial Advisors LLC now owns 1,986 shares of the biotechnology company’s stock valued at $460,000 after purchasing an additional 574 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.